Joincare Pharmaceutical Gr (600380.SS) traded flat 0 % during a 24 hours period ending at 10:05 PM Central Europe on Tuesday 27th. One Joincare Pharmaceutical Gr stock can currently be bought for about CNY 9.85 on popular exchanges. Current supply of Joincare Pharmaceutical Gr stocks is 1.8 bn. Joincare Pharmaceutical Gr has a current market capitalization of CNY 18.1 bn and approximately CNY 252.3 mn worth of Joincare Pharmaceutical Gr was traded on exchanges in the last 24 hours. Since last month end, Joincare Pharmaceutical Gr has traded -1.53 % down. Simple moving average of last 200 days is at CNY 9.84. The highest price of past 52 weeks was recorded at CNY 12.85 on 11/14/2025. 52 weeks low was at CNY 9 on 10/23/2026.
Summary of the latest news for Joincare Pharmaceutical Gr
Health Care Group Co., Ltd. reported its third‑quarter performance for 2026, noting a decline in operating revenue and net profit compared with the same period last year. The company highlighted a reduction in cash flows from operating activities and a slight contraction in total assets, while shareholders’ equity also fell. Management explained that the downturn was largely due to lower sales and a decrease in accounts receivable, offset partially by gains from investments and an increase in goodwill and use‑right assets following a subsidiary acquisition. The firm announced a shareholder return plan for the next three years, aiming to distribute a substantial portion of future profits to shareholders. Additionally, it issued a revised corporate charter and outlined a profit‑distribution proposal for the quarter. These disclosures underscore the company’s focus on restructuring and returning value to investors while navigating a challenging operating environment.
Here is how related stocks have performed in the past 24 hours:
Sbt Ultrasonic (688392.SS) traded flat 0 % and now trades at CNY 107.44. Sbt Ultrasonic has a market capitalisation of CNY 21.6 bn.
Harbin Electric -H (1133.HK) traded down -0.7 % and now trades at HKD 11.45. Harbin Electric -H has a market capitalisation of HKD 25.4 bn. Current price/earnings ratio for Harbin Electric -H is 6.5.
Hubei Zhenhua Chemical (603067.SS) traded flat 0 % and now trades at CNY 27.74. Current market capitalisation for Hubei Zhenhua Chemical is CNY 21.6 bn. Current price/earnings ratio for Hubei Zhenhua Chemical is 31.44. A recent release of third‑quarter fund reports has highlighted the ongoing recalibration of investment strategies within China’s capital markets. Analysts note that several prominent fund managers have adjusted their allocations in response to the market’s weaker momentum and the substantial pullback in technology growth stocks. While some managers have increased positions in AI‑related hardware, optical communication and domestic semiconductor leaders, others have shifted focus toward defensive sectors such as utilities, coal and pharmaceuticals, and to low‑valuation financial assets. The reports also suggest that managers are maintaining a cautious stance on highly crowded technology assets, favouring firms with clear value‑creation potential and stable earnings. In the pharmaceutical space, there is an emphasis on innovative drug development and service chains, with attention to emerging trends like AI‑assisted research and the solidifying demand for specialty products. Overall, the third‑quarter filings reflect a strategic diversification aimed at balancing growth opportunities with risk mitigation amid a challenging market environment.
North Copper (000737.SZ) traded flat 0 % and now trades at CNY 11.18. North Copper has a market capitalisation of CNY 21.5 bn. North Copper has a current price to earnings ratio of 12.66.
Hybio Pharmaceutical Lt (300199.SZ) traded flat 0 % and now trades at CNY 23.2. Current market capitalisation for Hybio Pharmaceutical Lt is CNY 21.6 bn. Hybio Pharmaceutical Lt has a current price to earnings ratio of 172.03. HyBio Pharmaceutical Co. Ltd. reported a strong performance in its third‑quarter earnings, with revenue and profit figures rising markedly. The company highlighted a substantial increase in sales of GLP‑1 peptide raw materials, which have become a key driver of its growth. In line with this momentum, HyBio announced plans to expand its peptide production capacity, investing up to 3.8 billion yuan in a new green‑intelligent production line that will double annual output. The firm also disclosed progress on its innovative oral peptide candidate, HY3003, whose preclinical studies showed superior weight‑loss effects compared with the market‑leading semaglutide. These developments reinforce HyBio’s strategy of integrating raw‑material supply, formulation, and drug development to capture expanding demand in the metabolic‑disease treatment market.
About Joincare Pharmaceutical Gr
The Joincare Pharmaceutical Group Industry Co Ltd is a health care company based in Shenzhen, China. They specialize in the development of drug products. The company produces Chinese patent medicine, detection reagents, raw material medicine, chemical preparations, and other products. Additionally, Joincare Pharmaceutical Group Industry Co Ltd also produces health care products. You can find more information about their offerings on their website, www.joincare.com , and they are listed on the Shanghai Stock Exchange. Their Initial Public Offering (IPO) date was May 9, 2001.